Pinnacle Associates’s Revolution Medicines RVMD Stock Holding History

Pinnacle Associates’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$374K	Buy	+1,821	New	+$361K	﹤0.01%	743

Other funds holding RVMD

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Pinnacle Associates's RVMD Position: Q3 2026 in Review

Pinnacle Associates opened a new position in Revolution Medicines (RVMD) in Q3 2026: 1,821 shares worth $374K. The stake represents ﹤0.01% of the portfolio and ranks #743 among its holdings.

329 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

Pinnacle Associates held 1,821 shares of Revolution Medicines worth $374K as of Q3 2026.
Revolution Medicines was a new Pinnacle Associates position in Q3 2026.
Revolution Medicines made up ﹤0.01% of Pinnacle Associates's portfolio in Q3 2026, its #743 holding.
329 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Pinnacle Associates's 13F filing for Q3 2026, filed 20 Oct 2026.